No Data
No Data
Qyuns Therapeutics Shrinks Loss in H1
Performance: Quanxin Biotech (02509.HK) narrowed its half-year loss to 0.172 billion RMB.
China Medical System Holdings Ltd. - B (02509.HK) announced its interim results for the six months ended in June, with revenue reaching 449.2 million yuan (same below). The loss narrowed from 0.258 billion yuan in the same period last year to 0.172 billion yuan, with a loss per share of 79 cents. No interim dividend will be paid.
China Create Bio-B (02509) released its interim results, achieving revenue of 44.919 million yuan.
Quanxin Biopharmaceutical-B (02509) released the unaudited interim results for the six months ending June 30, 2024,...
Qunxing Biologics-B (02509.HK) announced its interim performance. It continues to optimize the CMC quality management system and improve production efficiency, seeking opportunities for overseas expansion.
On August 15th, Grontmij released an announcement. For a six-month period ending on June 30, 2024, the group's revenue was 449.2 million yuan, which was generated from royalty income and research and development service fees from QX008N and QX004N authorized transactions, reflecting the group's strong research and development capabilities. As of July 31, 2024, the company holds 43 patents in China, including 34 invention patents and 9 utility model patents, and 9 patents overseas. As of the same date, the company also has 46 patent applications in China and overseas awaiting approval.
QYUNS-B: UNAUDITED INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30, 2024
Quanxin Biology-B (02509.HK) will hold a board of directors' meeting on August 15 to approve its interim performance.
On August 5th, Guolong Announcement, Bio-B (02509.HK) announced that the company's board of directors meeting will be held on August 15, 2024 to consider and approve the group's six-month interim performance ending on June 30, 2024 and its release, as well as handling other matters.
No Data
No Data